ReviewFrontiers in endocrinology2022
Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Random Forest for Predicting Treatment Response to Radioiodine and Thyrotropin Suppression Therapy in Patients With Differentiated Thyroid Cancer But Without Structural Disease.The oncologist · 2024Trial
- The Role ofMedical sciences (Basel, Switzerland) · 2026Review
- Analysis of the impact of Graves' disease on the efficacy of initial radioactive iodine therapy in patients with differentiated thyroid cancer.American journal of cancer research · 2026Article
- Clinical and metabolic factors associated with response to postoperative radioactive iodine therapy in Chinese obese patients with papillary thyroid carcinoma.Frontiers in endocrinology · 2026Observational
- Reflective analysis on the currentEuropean journal of nuclear medicine and molecular imaging · 2025Article
- The Impact of Radioactive Iodine on Outcomes Among Pediatric and Adolescent Thyroid Cancer Patients: A SEER Database Analysis.Cancers · 2025Article
- Latent Profile Analysis of Post-Surgical Psychological Distress in Young Thyroid Cancer Patients and Its Association with Self-Management Efficacy.Journal of multidisciplinary healthcare · 2025Article
- Beyond the Burn: Leukemia Threats Following Radioactive Iodine Ablation Therapy for Thyroid Cancer.Cancers · 2024Article
- Treatment outcomes in patients with papillary thyroid cancer undergoing radiofrequency ablation of metastatic lymph nodes.Gland surgery · 2024Article
- Advances in the Diagnosis and Treatment of Follicular Thyroid Carcinoma: A Comprehensive Review.Cureus · 2024Review
- Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation.Frontiers in endocrinology · 2024Article
- Could Oxidative Stress Play a Role in the Development and Clinical Management of Differentiated Thyroid Cancer?Cancers · 2023Review
- Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radioiodine (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.